Comparing a new drug to chemo for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug, 9MW2821, against standard chemotherapy for people with advanced bladder cancer that has gotten worse after previous treatments. It aims to see if the new drug works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced bladder cancer that cannot be removed by surgery.
- You have already been treated with both platinum chemo and an immunotherapy drug (like a PD-1 or PD-L1 inhibitor).
- Your cancer has grown or spread while on your last treatment.
- You are willing to provide a tumor sample from a previous biopsy or have a new one taken.
- You are able to take care of yourself (ECOG score 0 or 1) and have a life expectancy of at least 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of two drugs—9MW2821 (a targeted therapy) and toripalimab (an immunotherapy)—for people with advanced bladder cancer. It aims to see if using them together can help shrink tumors or slow the cancer's growth.
This trial tests a new drug called SYS6002 against the standard treatment Padcev for people with advanced bladder cancer that has already been treated with chemotherapy and immunotherapy. It aims to see if the new drug works better or has fewer side effects.
This trial tests a new drug called SHR-A2102, which is a type of targeted therapy (an antibody-drug conjugate) for advanced urothelial carcinoma (bladder cancer). It may help if your cancer has not responded to standard treatments or if you are starting treatment for advanced disease.
This trial tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced bladder cancer that has stopped responding to platinum chemo and immunotherapy. The goal is to see if the new drug works better.
This trial is testing a new combination of two drugs (9MW2821 and toripalimab) against standard chemotherapy for people with advanced bladder cancer that has not been treated before. The goal is to see if this new approach works better at shrinking tumors or slowing the cancer's growth.
This trial tests a new experimental drug combination (BL-B01D1 with a PD-1 immunotherapy) for advanced bladder cancer that has not yet been treated with whole-body therapy. The goal is to see if this combination can shrink tumors and help people live longer without their cancer getting worse.
Hear when a new Advanced Urothelial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.